STOCK TITAN

Zymeworks R&D head sells 13,832 shares to cover taxes

The EVP, Head of R&D's sale was confined to mandatory sell-to-cover provisions for required taxes and fees.

(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

On October 9, 2026, Zymeworks Inc. EVP, Head of R&D Adam Schayowitz had 37,037 restricted stock units vest, issuing 37,037 common shares. He sold 13,832 shares at a weighted average price of $25.85 per share to cover required taxes and fees under mandatory sell-to-cover provisions; the sale was not discretionary. His reported post-transaction balance was 74,074 RSUs.

Insider Schayowitz Adam
Role EVP, Head of R&D
Sold 13,832 shs ($358K)
Approx. gross sale proceeds $358K
Type Security Shares Price Value
Exercise Restricted Stock Unit F4, F5 37,037 $0.00 $0.00
Exercise Common Stock F1 37,037 $0.00 $0.00
Sale Common Stock F2, F3 13,832 $25.85 $358K
Holdings After Transaction: Restricted Stock Unit — 74,074 contracts (Direct); Common Stock — 23,205 shares (Direct)
Footnotes (5)
  1. F1. Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on October 9, 2025.
  2. F2. Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees.
  3. F3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.85 to $25.88, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  4. F4. Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of common stock.
  5. F5. Restricted stock units ("RSUs") granted October 9, 2025; vest in three equal annual installments beginning October 9, 2026.
RSUs vested 37,037 shares October 9, 2026
Common shares issued 37,037 shares Upon vesting of RSUs on October 9, 2026
Common shares sold 13,832 shares October 9, 2026
Weighted average sale price $25.85 per share Sale on October 9, 2026
Sale price range $25.85 to $25.88 per share Multiple transactions on October 9, 2026
RSUs after transaction 74,074 shares Reported post-transaction balance
Restricted stock units ("RSUs") financial
"upon vesting of one third of the restricted stock units"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
sell to cover financial
"mandatory "sell to cover" provisions"
Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.
weighted average price financial
"The price reported in Column 4 is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many Zymeworks (ZYME) shares did Adam Schayowitz sell, and at what price?

Adam Schayowitz sold 13,832 common shares on October 9, 2026, at a weighted average price of $25.85 per share. The shares were sold in multiple transactions at prices from $25.85 to $25.88 to cover required tax withholding and other applicable fees under mandatory sell-to-cover provisions; the sale was not discretionary.

How did Adam Schayowitz's Zymeworks RSUs vest?

A total of 37,037 RSUs vested on October 9, 2026, issuing 37,037 common shares. The RSUs were granted on October 9, 2025, and vest in three equal annual installments beginning October 9, 2026; each RSU represents the contingent right to receive one common share upon vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Schayowitz Adam

(Last)(First)(Middle)
C/O ZYMEWORKS INC.
108 PATRIOT DRIVE, SUITE A

(Street)
MIDDLETOWN DELAWARE 19709

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Zymeworks Inc. [ ZYME ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
EVP, Head of R&D
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
10/09/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock10/09/2026M37,037A$0(1)37,037D
Common Stock10/09/2026S(2)13,832D$25.85(3)23,205D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Unit(4)10/09/2026M37,037 (5) (5)Common Stock37,037$074,074D
Explanation of Responses:
1. Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on October 9, 2025.
2. Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees.
3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.85 to $25.88, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
4. Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of common stock.
5. Restricted stock units ("RSUs") granted October 9, 2025; vest in three equal annual installments beginning October 9, 2026.
Remarks:
/s/ Catherine Graham, Attorney-in-Fact10/09/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading